CALDERWOOD & HARKNESS LLP Attorneys at Law 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Telephone: (215) 864-7200 Facsimile: (215) 864-7201 www.calderwoodharkness.com
PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
MEMORANDUM
December 10, 2023
To: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
From: Leonard Cross, Responsible Partner, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Calderwood & Harkness LLP
Re: Settlement Authority Parameters — IRS Transfer Pricing Examination, Tax Years 2017–2020 (Exam Team LB&I-NE-TP-2022-00641)
C&H Matter No.: 1018-00009
Taxpayer EIN: 22-3741856
Right-click to update Table of Contents
I. Purpose and Executive Summary
The purpose of this memorandum is to recommend settlement authority parameters for anticipated IRS Appeals proceedings following the Internal Revenue Service's issuance of its Notice of Proposed Adjustment ("NOPA") dated October 12, 2023, and the 30-Day Letter issued November 8, 2023, in connection with the transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC") for tax years 2017 through 2020.
As discussed in detail below, PPC's Formal Protest is scheduled to be filed on December 22, 2023, at which time the case will be transferred from the IRS Large Business & International Division ("LB&I") examination team to IRS Appeals for independent review and resolution. To enable Calderwood & Harkness LLP ("C&H") to negotiate effectively at the Appeals conference, PPC management must authorize specific settlement parameters in advance. This memorandum presents our analysis and recommendations regarding those parameters.
The IRS's proposed net adjustment across the four examination years totals $380.4 million, composed of the following three components:
• Cost-sharing arrangement ("CSA") cost-sharing ratio adjustments: $235.01 million
• Legacy intellectual property royalty rate adjustments: $188.04 million
• Less: Correlative offset to avoid double-counting: ($42.65 million)
In addition, the IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million, calculated as 20% of the underpayment attributable to the $380.4 million adjustment at a 21% corporate tax rate.
C&H recommends the following settlement authority:
• Target settlement range: 10–15% of the $380.4 million proposed adjustment, equating to a total income adjustment of $38.04 million to $57.06 million across all four tax years.
• Hard ceiling: 20% of the proposed adjustment ($76.08 million), above which C&H recommends PPC decline settlement and proceed to the United States Tax Court.
• Penalty: Full abatement of the IRC § 6662(e) penalty as a non-negotiable condition of any settlement. C&H believes PPC's contemporaneous documentation and reasonable-cause defense are sufficiently strong to justify this position.
These recommendations are grounded in a thorough hazards-of-litigation analysis, the strength of PPC's economic and legal positions across all three adjustment categories, the quality of PPC's contemporaneous transfer pricing documentation prepared by Crestfield & Associates, and the well-documented and substantial economic substance of Penterra Biosciences Ireland Ltd. ("PBI"), PPC's Irish subsidiary.
A separate, more detailed Hazards of Litigation Analysis memorandum, dated December 5, 2023 (Cross to Hartwell), provides probability-weighted assessments for each adjustment category and litigation scenario. That memorandum is incorporated herein by reference and should be reviewed in conjunction with this memorandum.
At the midpoint of the recommended target range (approximately 12.5%, or a $47.6 million adjustment), the total estimated cost to PPC — inclusive of federal tax, interest, and professional fees — would be approximately $20 million to $22 million, compared to a total potential exposure of approximately $103.4 million at full IRS assessment. This represents potential savings to PPC in excess of $80 million.
II. Background — The IRS Proposed Adjustments
A. Overview of the Examination
The IRS LB&I Northeast Transfer Pricing Practice opened its examination of PPC's tax years 2017 through 2020 on May 16, 2022, upon issuance of Letter 2205-A (Notification of Examination). The examination has been conducted by a dedicated transfer pricing examination team comprised of the following individuals:
• Supervisory Revenue Agent (Team Manager): Gerald Meskill
• Lead Revenue Agent: Patricia Dunleavy
• IRS Economist: Dr. Alan Washburne
• IRS Chief Counsel Attorney-Advisor: Franklin Rosario
• Senior Counsel (supporting): Donna Hirabayashi
The examination focused exclusively on PPC's intercompany transactions with PBI, including the cost-sharing arrangement governing the allocation of intangible development costs, the legacy intellectual property license agreement, and the broader question of PBI's economic substance as an IP-holding and operating entity.
Over the course of the examination, the IRS issued a total of forty-seven (47) Information Document Requests ("IDRs") between June 2022 and September 2023. C&H, in coordination with PPC's internal tax department and Crestfield & Associates, responded to each IDR within the prescribed timeframes. The examination process also included three on-site visits to PPC's U.S. headquarters in Princeton, New Jersey, and one visit to PBI's offices in Dublin, Ireland (conducted in April 2023). Additionally, C&H coordinated multiple telephone conferences and in-person meetings with the IRS examination team, including two pre-NOPA conferences in which C&H presented PPC's positions on the key issues.
The IRS issued its NOPA on October 12, 2023, proposing adjustments across all four tax years. Following issuance of the NOPA, C&H submitted a written response on November 1, 2023, but the examination team declined to modify its proposed adjustments. The IRS subsequently issued its 30-Day Letter on November 8, 2023, affording PPC thirty days to file a Formal Protest and request transfer to IRS Appeals.
B. The Three Categories of Proposed Adjustments
The IRS's proposed adjustments fall into three primary categories, as described below. Each category reflects a distinct transfer pricing issue, though the adjustments are interrelated to the extent that they all arise from the same intercompany relationship between PPC and PBI.
1. CSA Cost-Sharing Ratio Adjustments ($235.01 Million)
The IRS asserts that PBI's cost-sharing percentages under the cost-sharing arrangement (effective July 1, 2012) understate the value of PPC's U.S.-source contributions to the joint development of intangible property. Under the CSA, PPC and PBI share the costs of research and development ("R&D") in proportion to their respective reasonably anticipated benefits ("RABs") from the exploitation of resulting intangible property, as required by Treasury Regulation § 1.482-7.
PPC's contemporaneous documentation, prepared by Crestfield & Associates, established PBI's cost-sharing percentages based on detailed revenue projections for the non-Americas territory (PBI's exploitation area) relative to the Americas territory (PPC's exploitation area). The IRS examination team, relying on different revenue projections and alternative benefit-allocation methodologies, proposes increasing PBI's cost-sharing percentage by approximately 8 to 12 percentage points across the four examination years. The specific adjustments are as follows:
The IRS's proposed increase in PBI's cost-sharing percentages is predicated on the assertion that PPC's U.S.-based research activities generated a disproportionately greater share of the reasonably anticipated benefits than PPC's contemporaneous projections reflected. The IRS examination team relied on Dr. Washburne's economic analysis, which utilized alternative revenue growth assumptions, different market-penetration projections for key non-Americas markets, and a different weighting of clinical-stage versus commercial-stage pipeline products.
In addition, the IRS references its valuation of the 2012 platform contribution transaction ("PCT"), in which PPC transferred pre-existing intangible property to PBI in connection with the establishment of the CSA. The IRS valued the PCT at $852 million under the income method, compared to PPC's $312 million PCT payment. While the 2012 PCT year is outside the scope of the current examination years, the IRS cites the alleged PCT undervaluation as evidence that the ongoing cost-sharing ratios fail to account for the full value of the U.S.-contributed intellectual property. This argument is addressed in Section III.C below.
2. Legacy IP Royalty Rate Adjustments ($188.04 Million)
In addition to the CSA adjustments, the IRS proposes increasing the royalty rate payable by PBI to PPC under the legacy intellectual property license agreement. Under this agreement, PBI pays PPC a royalty for the right to exploit certain pre-CSA legacy intellectual property in non-Americas markets. PPC established a royalty rate of 4.5% of net sales, supported by a comparable uncontrolled transaction ("CUT") analysis conducted by Crestfield & Associates and subsequently validated by Whitmore Valuation Group.
The IRS proposes increasing the royalty rate from 4.5% to 11.0% of net sales, based on the IRS's own selection of CUT comparables. The IRS asserts that the comparable license agreements identified by PPC are insufficiently comparable and that the IRS's selected CUTs — which relate to pharmaceutical licensing transactions at higher royalty rates — better reflect arm's-length pricing. The resulting adjustments, reflecting a 6.5 percentage point increase applied to PBI's non-Americas legacy product net sales, are as follows:
The declining trajectory of non-Americas legacy net sales over the four-year period reflects natural product lifecycle attrition and the growing contribution of post-CSA products to PBI's revenue base.
3. Correlative Offset (−$42.65 Million)
Recognizing a degree of overlap between the CSA cost-sharing adjustments and the royalty rate adjustments — both of which seek to increase income allocable to PPC from the same intercompany relationship — the IRS allowed a correlative offset of $42.65 million across the four examination years. This offset is intended to prevent double-counting of income that would otherwise be captured by both the increased cost-sharing payments and the increased royalty payments. C&H notes that the methodology used by the IRS to compute this correlative offset lacks transparency, and we believe the offset should be larger; however, the IRS has not provided a detailed computation.
4. Economic Substance Challenge
The IRS's NOPA also asserts, in part, that PBI lacked sufficient economic substance to justify its role as the owner of intangible property rights for non-Americas markets and as a bona fide participant in the CSA. Specifically, the IRS argues that the key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — with respect to the intangible property remained substantially in the United States, performed by PPC's U.S.-based research, regulatory, and commercial teams.
This economic substance challenge is not presented as a standalone adjustment but rather as a supporting legal theory that underpins both the CSA and royalty rate adjustments. The IRS contends that PBI's cost-sharing participation and royalty rates should be evaluated in light of the actual allocation of DEMPE functions and the degree to which PBI independently exercised control over the development and exploitation of the intangible property.
C&H views the economic substance challenge as the weakest element of the IRS's overall position, as discussed in Section III.D below.
5. Penalty. The IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty. The penalty is calculated as 20% of the underpayment of tax attributable to the proposed transfer pricing adjustments. Based on the $380.4 million net proposed adjustment and a 21% federal corporate tax rate, the proposed penalty is approximately $15.98 million ($380.4M × 21% × 20% = $15.98M).
C. Net Proposed Adjustment Summary Table
The following table summarizes the IRS's proposed adjustments and the resulting tax and penalty exposure:
Note: For purposes of simplification in this memorandum, we have applied the 21% federal corporate tax rate across all four examination years, consistent with the methodology employed by the IRS in its NOPA. We acknowledge that the 2017 tax year involves a blended rate reflecting the transition from the 35% pre-Tax Cuts and Jobs Act ("TCJA") rate to the 21% post-TCJA rate effective January 1, 2018. The precise tax computation for TY 2017 would yield a slightly higher tax on the 2017 portion of the adjustment; however, this difference is not material to the settlement authority analysis and does not alter our recommendations.
Including estimated federal underpayment interest of approximately $7.5 million on the full tax deficiency from the original return due dates through an assumed settlement date, the total potential cash exposure to PPC at full IRS assessment is approximately $103.4 million.
III. Assessment of PPC's Defensive Positions
This section provides C&H's assessment of PPC's defensive positions on each of the IRS's proposed adjustments. These assessments draw upon the detailed analysis contained in the separate Hazards of Litigation Analysis memorandum dated December 5, 2023, the economic reports and rebuttal analyses prepared by Whitmore Valuation Group, and C&H's extensive experience in transfer pricing disputes at both the administrative and litigation levels.
A. CSA Cost-Sharing Ratios
PPC's cost-sharing percentages for PBI (ranging from 38.2% in 2017 to 42.7% in 2020) were determined based on reasonably anticipated benefits as required by Treasury Regulation § 1.482-7. The RAB calculations were predicated on detailed, market-by-market revenue projections for each participant's territory, taking into account product-specific lifecycle forecasts, regulatory timelines, market-penetration estimates, and macroeconomic factors specific to each geographic region.
These revenue projections were contemporaneously documented by Crestfield & Associates, under the supervision of Susan Lam, Transfer Pricing Partner. The Crestfield documentation, prepared annually for each of the four examination years, applied a consistent methodology that had been utilized since the CSA's inception in 2012 and was supported by PPC's internal business planning data, board-approved budgets, and third-party market research.
In addition to the Crestfield documentation, PPC engaged Whitmore Valuation Group to perform an independent analysis testing PBI's arm's-length returns. Dr. Helena Vasquez and Dr. Rohan Chakrabarti of Whitmore conducted a comparable profits method ("CPM") and transactional net margin method ("TNMM") analysis, identifying twenty-two (22) comparable distributors and IP-holding companies operating in the pharmaceutical and life sciences sectors. PBI's operating margins fell within the interquartile range of the comparable set in all four examination years, corroborating the reasonableness of the cost-sharing percentages.
The IRS's proposed cost-sharing percentages (48.2% to 53.7% for PBI) rely on inflated U.S.-source benefit projections that, in C&H's view, significantly overweight the contribution of U.S.-based research activities while failing to adequately account for PBI's independent commercial contributions to revenue generation in the non-Americas territory. Specifically, Dr. Washburne's analysis assumes unrealistically high growth rates for non-Americas markets, which paradoxically inflates the RAB attributable to U.S. research contributions by assuming that PBI's markets would generate benefits disproportionate to PBI's actual revenue history. The IRS's methodology also fails to properly account for PBI's independent contributions to regulatory approvals, commercial launch activities, pricing negotiations, and market access strategies across 68 country markets.
Strength Assessment: Strong. PPC's methodology is well-documented, consistently applied, and supported by independent economic analysis from a qualified valuation firm. The underlying revenue projections are reasonable and consistent with actual outcomes.
Hazard of Litigation: C&H assesses a 15–25% probability that the IRS would prevail on the full CSA cost-sharing adjustment if the matter proceeded to litigation. More realistically, any adverse outcome would likely involve a partial adjustment in the range of 5–15% of the $235.01 million CSA amount, reflecting some modest recalibration of the RAB percentages without adopting the IRS's extreme position.
B. Legacy IP Royalty Rate
PPC's 4.5% royalty rate under the legacy IP license agreement is supported by a robust CUT analysis conducted by Whitmore Valuation Group. Dr. Vasquez and Dr. Chakrabarti identified fourteen (14) comparable uncontrolled pharmaceutical license agreements through a comprehensive search of publicly available licensing databases, SEC filings, and industry transaction databases. The interquartile range of royalty rates in the comparable set was 3.1% to 6.8%, with a median of 4.4%.
PPC's royalty rate of 4.5% is essentially at the median of this comparable set and well within the interquartile range. The Whitmore analysis applied rigorous comparability criteria, including similarity of therapeutic area (small-molecule pharmaceuticals), development stage (fully commercialized products), geographic scope (international licensing rights), exclusivity terms, and risk allocation. Adjustments were made where appropriate to enhance comparability.
The IRS's proposed rate of 11.0% is based on the IRS's own selection of CUT comparables that are distinguishable from PBI's license on material comparability grounds. Specifically, the IRS's CUTs include transactions involving:
• Biologics and biosimilar products (distinct therapeutic areas with different development cost structures and market dynamics)
• Early-stage and clinical-stage development compounds (materially different risk profiles than fully commercialized products)
• Transactions that bundled manufacturing rights, data exclusivity, and marketing authorizations (broader scope of rights than PBI's license)
• Agreements negotiated in market conditions that are not contemporaneous with PBI's license execution
C&H believes the IRS's CUTs would not withstand rigorous comparability analysis under established Tax Court precedent. In particular, the principles articulated in Harborview Corporation, Inc. v. Commissioner, 254 F. Supp. 3d 1027 (D. Minn. 2017), and subsequent proceedings, underscore the importance of rigorous comparability analysis in CUT-based transfer pricing determinations. The Tax Court has consistently rejected CUT analyses predicated on agreements that are materially distinguishable from the controlled transaction under review.
Strength Assessment: Very Strong. PPC's CUT analysis is methodologically sound, supported by a large and well-screened comparable set, and yields a rate that falls at the median of the interquartile range. The IRS's CUTs are weak comparables that would be vulnerable to challenge at trial.
Hazard of Litigation: C&H assesses a 10–20% probability that the IRS would prevail in obtaining any upward adjustment to PPC's 4.5% royalty rate. Even in an adverse scenario, any adjustment would likely be modest — perhaps 1 to 2 percentage points at most — resulting in a rate still well below the IRS's proposed 11.0%.
C. PCT Valuation
The original PCT payment of $312 million, made by PBI to PPC on July 1, 2012, compensated PPC for the transfer of pre-existing intangible property to PBI in connection with the CSA. While the 2012 PCT year is outside the scope of the current examination (TY 2017–2020), the IRS references the PCT valuation in its NOPA as support for its position that the ongoing cost-sharing ratios understate the value of PPC's contributions.
The IRS valued the PCT at $852 million using the income method prescribed by Treasury Regulation § 1.482-7(g)(4), applying a weighted average cost of capital ("WACC") of 7.2% as the discount rate. This valuation represents a significant uplift over PPC's $312 million PCT payment and, if accepted, would imply that PBI acquired the pre-existing intangible property at a substantial discount.
C&H and Whitmore Valuation Group have conducted an independent discounted cash flow ("DCF") revaluation of the PCT using a WACC of 9.8%, which C&H believes more accurately reflects the risk profile of PBI's non-Americas exploitation rights. Under Whitmore's analysis, the $312 million PCT payment falls within the arm's-length range of $278 million to $361 million.
The WACC dispute is central to the PCT valuation issue. Dr. Vasquez's analysis demonstrates that the IRS's 7.2% discount rate is inappropriately low for several reasons:
• It fails to adequately incorporate pharmaceutical-industry risk premiums, which reflect the inherent uncertainty of regulatory approval, market access, and commercial success in international markets
• The IRS's beta comparables include diversified healthcare conglomerates with revenue streams that are materially less volatile than PBI's concentrated pharmaceutical product portfolio
• The IRS does not account for the specific risk profile of PBI's non-Americas exploitation rights, which include markets with significant regulatory uncertainty, currency risk, and pricing pressure from government healthcare systems
Strength Assessment: Strong. The WACC dispute clearly favors PPC. The IRS's discount rate is below widely accepted pharmaceutical-industry benchmarks, and Dr. Vasquez's analysis is well-supported by market data and financial literature.
Hazard of Litigation: C&H assesses a 20–30% probability that the IRS would partially prevail on the PCT valuation issue. However, the direct financial impact is limited because the 2012 PCT year is not an examination year. The PCT valuation is relevant only to the extent it informs the IRS's arguments regarding the ongoing CSA cost-sharing ratios, and C&H believes the CSA ratios can be defended independently of the PCT issue.
D. Economic Substance of PBI
PBI maintained substantial operations in Dublin, Ireland throughout the 2017–2020 examination period. The factual record demonstrates that PBI was a genuine operating entity with significant business activities, decision-making authority, and independent economic functions. Key facts include:
• Personnel: PBI employed 185 employees as of December 31, 2020, having grown from 52 employees at the time of its incorporation in 2012. PBI's workforce included professionals in regulatory affairs, commercial operations, supply chain management, finance, legal, and medical affairs.
• Governance: PBI's board of directors held a total of 42 board meetings in Dublin during the examination period, consisting of quarterly board meetings and special sessions as needed. Board meetings were conducted in-person in Dublin and addressed substantive business matters, including budget approvals, strategic planning, regulatory submissions, and commercial launch decisions.
• Regulatory Operations: PBI incurred cumulative regulatory expenditures of approximately €47.2 million on regulatory submissions across 68 country markets during the examination period. These expenditures included costs associated with marketing authorization applications, post-marketing surveillance, pharmacovigilance, and label updates.
• Physical Presence: PBI occupied approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, pursuant to a third-party commercial lease.
• Management: PBI's Managing Director, Aidan Naughton, was based in Dublin and exercised day-to-day management authority over PBI's operations.
• Financial Independence: PBI maintained independent banking relationships with Glenmore Bank Ireland plc, including operating accounts, treasury management facilities, and foreign exchange hedging arrangements.
• Commercial Decision-Making: PBI made independent pricing decisions across its 68 non-Americas markets, taking into account local market conditions, competitive dynamics, government reimbursement frameworks, and regulatory requirements.
C&H conducted a comprehensive functional analysis of PBI in October 2022, which was updated in March 2023, documenting PBI's decision-making authority, risk management practices, and control over DEMPE functions for the non-Americas territory. The functional analysis was based on extensive document review, on-site observations, and interviews with PBI personnel.
In connection with the functional analysis, C&H conducted twelve (12) interviews with PBI personnel in August and September 2022. These interviews covered individuals across multiple functions and levels of seniority and confirmed that PBI personnel exercised substantive decision-making authority and performed meaningful commercial, regulatory, and strategic functions independent of PPC's U.S. operations.
Strength Assessment: Very Strong. PBI's economic substance is well-evidenced across multiple dimensions — personnel, governance, regulatory activities, physical presence, management authority, financial independence, and commercial decision-making. The level of substance significantly exceeds the threshold established in comparable cases involving challenges to the economic substance of foreign affiliates.
Hazard of Litigation: C&H assesses only a 5–15% probability that the IRS would prevail on pure economic substance grounds. The factual record strongly supports PBI's status as a genuine operating entity with independent control over its DEMPE functions. The IRS's economic substance argument is a supporting theory rather than a standalone basis for adjustment, and it is unlikely to carry the day at trial absent a more compelling factual foundation.
E. Penalty Protection
PPC maintained contemporaneous transfer pricing documentation for all four examination years. The documentation was prepared by Crestfield & Associates under standards specifically designed to satisfy the penalty-protection requirements of IRC § 6662(e) and the regulations thereunder.
Specifically, the documentation satisfies the requirements of Treasury Regulation § 1.6662-6, including:
• An overview of PPC's business, including a description of the organizational structure, the nature of PPC's products and services, and the economic and regulatory conditions in which PPC operates
• A description of the controlled transactions, including the CSA cost-sharing arrangement and the legacy IP license agreement
• A description of the transfer pricing methods considered and selected, including the CUT method for the royalty rate and the RAB method for cost-sharing percentages
• An analysis of the comparability factors considered and the economic data relied upon
• A description of the controlled taxpayer's general index of principal documents
In addition to the Crestfield documentation, PPC relied on qualified professionals — including Crestfield & Associates, Whitmore Valuation Group, and C&H — in determining its transfer pricing methodology and in applying that methodology to the controlled transactions. This reliance on qualified professionals provides an independent basis for a reasonable-cause defense under IRC § 6662(e)(3)(B).
Strength Assessment: Very Strong. PPC's contemporaneous documentation is comprehensive, professionally prepared, and meets or exceeds the penalty-protection standards prescribed by the applicable regulations. The reasonable-cause defense is compelling. Full penalty abatement should be achievable regardless of any concession PPC may make on the underlying income adjustment.
Hazard of Litigation: C&H assesses less than a 10% probability that the IRC § 6662(e) penalty would be sustained in litigation. The documentation record is strong, and the reliance on qualified professionals provides an additional layer of protection.
IV. Appeals Process Considerations
A. Nature of IRS Appeals
The IRS Office of Appeals (now formally known as the IRS Independent Office of Appeals following the Taxpayer First Act of 2019) functions as an independent dispute resolution forum within the IRS. The Appeals Officer assigned to PPC's case will evaluate the hazards of litigation for both the IRS and PPC under the framework established by Revenue Procedure 2015-41 and related guidance. The Appeals Officer is not bound by the examination team's proposed adjustments and is authorized to settle cases based on the relative litigation hazards of each issue.
In transfer pricing cases, Appeals Officers frequently settle at significant discounts to proposed adjustments, particularly where the taxpayer demonstrates strong defensive positions supported by credible economic analysis and robust documentation. Transfer pricing disputes are inherently fact-intensive and involve substantial uncertainty regarding valuation, comparability, and methodology, which typically leads Appeals Officers to apply meaningful haircuts to the examination team's positions.
Following the filing of PPC's Formal Protest on December 22, 2023, the case will be transferred from the LB&I examination team to IRS Appeals. Based on current processing timelines, C&H anticipates that the case will be formally assigned to an Appeals Officer in January 2024. Upon assignment, C&H will request scheduling of an Appeals conference, which we anticipate will take place in late February 2024.
B. Strategic Dynamics
Several strategic dynamics favor PPC in the Appeals process:
Weaknesses in the IRS's Position. The IRS examination team's positions contain significant vulnerabilities, particularly with respect to the royalty rate CUT analysis and the PBI economic substance challenge. The IRS's selected CUT comparables are distinguishable on multiple comparability grounds, and the economic substance of PBI is well-documented across multiple dimensions. These vulnerabilities will be apparent to a competent Appeals Officer and should translate into substantial settlement leverage.
CSA Cost-Sharing as the Primary Negotiation Issue. The CSA cost-sharing issue presents the most nuanced area of dispute, involving complex valuation and RAB projection questions. This is the issue area where a partial concession by PPC may be strategically appropriate to achieve a global resolution. C&H recommends framing any concession in the CSA area as a hazards-of-litigation-based settlement, rather than an acknowledgment that PPC's original methodology was incorrect. Any agreed adjustment should be structured as a lump-sum income adjustment rather than a prospective change to PPC's cost-sharing methodology.
Penalty as a Threshold Issue. Penalty abatement should be presented to the Appeals Officer as a threshold issue and a non-negotiable condition of any settlement. PPC's contemporaneous transfer pricing documentation unambiguously satisfies the penalty-protection standards, and C&H believes the Appeals Officer will recognize this. Establishing penalty abatement early in the process will facilitate constructive negotiations on the underlying income adjustment.
Correlative Offset. The IRS's allowance of a correlative offset of $42.65 million already acknowledges the overlap between the CSA and royalty adjustment categories. This is a tacit concession that the two adjustments, taken together at full value, overstate the income properly allocable to PPC. C&H intends to use this acknowledged overlap as additional leverage in negotiations.
C. Precedent and Leverage
Several recent developments in transfer pricing case law provide PPC with additional negotiating leverage at Appeals:
Tax Court Precedent. Recent decisions of the United States Tax Court, including Altera Corp. v. Commissioner, 145 T.C. 91 (2015), aff'd, 926 F.3d 1061 (9th Cir. 2019), and Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112, have imposed rigorous analytical standards on the IRS's ability to sustain aggressive transfer pricing adjustments. These decisions underscore the requirements for robust comparable support, sound economic methodology, and thorough comparability analysis. The IRS's positions in PPC's case are vulnerable to challenge under these standards.
Rebuttal of IRS Economist. Dr. Washburne's economic analysis, which forms the foundation of the IRS's CSA and royalty adjustments, has been rebutted on a point-by-point basis by Dr. Vasquez and Dr. Chakrabarti of Whitmore Valuation Group. The Whitmore rebuttal memorandum is currently being finalized and is expected to be completed in January 2024. C&H will submit this rebuttal to the Appeals Officer as part of the Appeals conference materials.
Willingness to Litigate. PPC's willingness to proceed to the United States Tax Court, if necessary, provides meaningful negotiating leverage at Appeals. Appeals Officers are aware that a taxpayer with strong litigation positions and the financial resources to sustain litigation will not accept an unreasonable settlement. C&H will communicate PPC's litigation readiness to the Appeals Officer, while simultaneously demonstrating PPC's good-faith willingness to resolve the dispute at the administrative level.
V. Recommended Settlement Authority Parameters
Based on the analysis set forth in Sections II through IV above, and the detailed probability assessments contained in the separate Hazards of Litigation Analysis memorandum, C&H recommends the following settlement authority parameters for the Appeals proceedings.
A. Target Range: 10–15% of Proposed Adjustment
C&H recommends a target settlement range of 10% to 15% of the IRS's $380.4 million net proposed adjustment, corresponding to:
• Total income adjustment: $38.04 million to $57.06 million across all four tax years
• Tax impact at 21%: $7.99 million to $11.98 million
This target range reflects the probability-weighted hazards of litigation across all three adjustment categories, taking into account the relative strengths of PPC's positions on the CSA cost-sharing ratios, the legacy IP royalty rate, and the PCT valuation, as well as the very strong defense on PBI's economic substance. The range is consistent with the expected value of potential outcomes if the case were to proceed to litigation, adjusted for the cost, time, and uncertainty associated with Tax Court proceedings.
At the midpoint of the target range (approximately 12.5%, or approximately $47.6 million), the total federal tax cost to PPC would be approximately $10.0 million, plus accrued interest. C&H believes a settlement at or near this midpoint would represent a fair and defensible resolution that reflects the genuine hazards of litigation on both sides.
B. Hard Ceiling: 20% of Proposed Adjustment
C&H recommends a hard ceiling of 20% of the IRS's proposed adjustment, corresponding to:
• Total income adjustment: $76.08 million
• Tax impact at 21%: $15.98 million
This ceiling represents the maximum concession C&H recommends PPC authorize under the current facts and circumstances, absent extraordinary developments that materially alter the litigation hazards. At a 20% settlement, PPC would still achieve an 80% reduction from the IRS's proposed adjustment — a result that would be widely regarded as a very favorable outcome in a transfer pricing dispute of this magnitude.
If the Appeals Officer is unwilling to settle at or below the 20% threshold, C&H recommends that PPC decline settlement and proceed to the United States Tax Court. As discussed in Section VIII below, litigation involves additional costs and risks, but PPC's positions are sufficiently strong to justify proceeding to trial if the Appeals process does not yield an acceptable resolution.
C. Penalty: Full Abatement Required
No settlement authority should include acceptance of any portion of the IRC § 6662(e) substantial valuation misstatement penalty. Full abatement of the proposed $15.98 million penalty is a non-negotiable component of any settlement, and C&H recommends that PPC's negotiating team communicate this position clearly to the Appeals Officer at the outset of the process.
PPC's contemporaneous transfer pricing documentation and reasonable-cause defense are strong enough to insist on full penalty abatement as a condition of settlement. The documentation was prepared in accordance with penalty-protection standards by a qualified transfer pricing firm, and PPC relied on multiple qualified professionals in determining its transfer pricing positions. These facts provide a compelling basis for penalty abatement under both the documentation and reasonable-cause prongs of the penalty protection framework.
If the Appeals Officer is unwilling to fully abate the penalty, this alone may justify proceeding to Tax Court, even if the underlying income adjustment is within the target settlement range. The penalty issue is one on which PPC has its strongest defense, and acceptance of any penalty amount would set an adverse precedent for future examination cycles.
D. Allocation Across Tax Years
Any settlement should be allocated across the four tax years in a manner consistent with the relative size of the IRS's proposed adjustments for each year. The allocation methodology should reflect the relative weight of the CSA and royalty adjustments in each year, taking into account the year-specific cost-sharing percentages, R&D cost bases, and legacy product net sales volumes.
At the midpoint of the target range (approximately 12.5%, or approximately $47.6 million total adjustment), C&H recommends the following approximate allocation:
This allocation reflects the relative magnitude of the combined CSA and royalty adjustments proposed for each year. The precise allocation will be a negotiation point at Appeals and may be adjusted within the overall settlement amount without requiring additional authorization, provided the total adjustment remains within the approved parameters.
E. Interest
Federal underpayment interest will be computed on any agreed tax deficiency from the original due dates of the returns (as extended) through the date of payment. Interest is imposed by statute under IRC § 6601 and is not a settlement variable — it is non-negotiable and will be assessed regardless of the settlement terms.
Based on the applicable federal underpayment rates in effect during the relevant periods, C&H estimates that accrued interest on a $10.0 million tax settlement (the approximate tax at the 12.5% midpoint) would be approximately $2.84 million. At the 20% ceiling, estimated interest would be approximately $4.5 million. At full IRS assessment, estimated interest would be approximately $7.5 million.
The accrual of statutory interest argues in favor of expeditious resolution. Each month of delay increases PPC's total cash outlay on any eventual settlement, and this incremental cost provides additional justification for pursuing a prompt resolution at the Appeals level rather than prolonging the dispute through litigation.
VI. Financial Impact Analysis
A. Comparison Table: Full Assessment vs. Target Settlement
The following table compares PPC's total cash exposure under three scenarios: full IRS assessment, settlement at the target midpoint (12.5%), and settlement at the hard ceiling (20%):
A settlement at the target midpoint would save PPC approximately $90.5 million compared to full IRS assessment. Even at the hard ceiling, the savings would be approximately $82.9 million.
B. Impact on FIN 48 / ASC 740-10 Reserve
PPC currently maintains an uncertain tax position ("UTP") reserve under ASC 740-10 (formerly FIN 48) of $62.4 million related to the Irish IP structure, including reserves for both the CSA cost-sharing and legacy royalty issues. This reserve was established based on PPC's assessment of the probability-weighted expected outcomes for each uncertain tax position and has been carried on PPC's balance sheet in accordance with the recognition and measurement criteria of ASC 740-10.
Upon settlement at approximately $47.6 million (the target midpoint), PPC's UTP reserve would be adjusted to reflect the resolution of the settled positions. C&H estimates that the post-settlement reserve would be reduced to approximately $14.8 million, reflecting the remaining uncertainty associated with open examination years and any positions not fully resolved by the settlement (including potential implications for subsequent tax years and any ongoing competent authority proceedings).
This reserve reduction of approximately $47.6 million would have a positive impact on PPC's financial statements and reported earnings, as the excess reserve would be released through the tax provision in the period in which the settlement is executed. The reserve reduction would flow through the income tax provision on PPC's consolidated statement of operations, resulting in a one-time reduction in the effective tax rate.
C&H has been in coordination with Crestfield & Associates regarding the year-end 2023 reserve assessment. Martin Ogilvy, the engagement partner at Crestfield responsible for PPC's ASC 740-10 work, has been briefed on the settlement authority analysis and the hazards-of-litigation assessments. C&H provided an updated FIN 48 support letter to PPC, dated November 20, 2023, which is intended to support PPC's reserve calculations for the year-end 2023 financial statements.
C. Impact on Hargrove National Bank Credit Facility
PPC maintains a $1.5 billion revolving credit facility with Hargrove National Bank, N.A. (Christine Bellucci, Senior Vice President, Relationship Manager). The credit agreement governing this facility contains certain tax-related covenants, including a tax-indemnity provision and a material-tax-event covenant that requires PPC to notify the lender and, in certain circumstances, prepay outstanding balances if PPC experiences a material adverse tax event.
A settlement within the recommended range of 10–15% of the proposed adjustment should not trigger a material-tax-event default or reporting obligation under the credit facility. A separate Hargrove Covenant Analysis memorandum, prepared by C&H associate Nazari in November 2023, analyzes the specific covenant language and concludes that a tax settlement at the recommended levels does not constitute a "Material Tax Event" as defined in the credit agreement.
However, the IRS's full proposed adjustment of $380.4 million, if sustained in its entirety, could potentially implicate the material-tax-event covenants. The resulting tax liability of approximately $79.88 million, combined with penalty and interest, could arguably constitute a material adverse change in PPC's financial condition, depending on the interpretation of the covenant language. Resolution at 10–20% of the proposed adjustment eliminates this concern entirely and preserves PPC's relationship with Hargrove National Bank on favorable terms.
D. SEC Disclosure Considerations
PPC's upcoming Annual Report on Form 10-K for the fiscal year ended December 31, 2023 will need to address the IRS examination as a contingent liability under ASC 450-20 (formerly SFAS 5). PPC's disclosure obligations require discussion of the nature of the contingency, an estimate of the possible loss or range of loss, and an assessment of the likelihood of a material adverse outcome.
A settlement within the target range of 10–15% is consistent with PPC's existing FIN 48 reserves and should not require material additional disclosure beyond the existing cautionary language regarding IRS transfer pricing examinations that has appeared in PPC's prior filings. If the settlement is finalized prior to the 10-K filing date, the settlement terms would be disclosed as a resolved contingency.
C&H notes that Ridgeview Capital Management LP, an 8.3% institutional shareholder in PPC (Douglas Everett, Managing Partner), actively monitors PPC's tax reserve disclosures and has historically engaged with PPC management regarding tax-related contingencies. A favorable settlement within the recommended range would support investor confidence and is consistent with the tax risk profile that PPC has communicated to the investment community.
VII. Competent Authority / Mutual Agreement Procedure Considerations
A transfer pricing adjustment under IRC § 482 may give rise to economic double taxation of PBI in Ireland if the Irish Revenue Commissioners do not grant a corresponding adjustment to reduce PBI's Irish taxable income. The United States–Ireland Income Tax Treaty (the "Treaty") provides for competent authority relief under the mutual agreement procedure ("MAP") set forth in Article 25 of the Treaty.
If PPC agrees to a settlement that increases PPC's U.S. taxable income, the corresponding reduction in PBI's income may not be automatically recognized by the Irish tax authorities. In such a case, PPC would be entitled to request that the U.S. Competent Authority (currently the IRS's Treaty Assistance and Interpretation Team within the Office of the Deputy Commissioner, International) initiate MAP proceedings with the Irish Competent Authority to eliminate or reduce the resulting double taxation.
C&H recommends that the decision of whether to pursue a MAP request be evaluated following the conclusion of the Appeals settlement, in coordination with Thornbury & Keogh (Ciarán Thornbury, Lead Partner), PPC's Irish tax advisors based in Dublin. The settlement amount and its allocation across the four tax years will determine the scope of any MAP relief available and the magnitude of the potential double taxation at issue.
C&H does not recommend conditioning the Appeals settlement on the outcome of MAP proceedings. MAP proceedings are typically lengthy (18–24 months or longer) and their outcome is uncertain, as they depend on bilateral negotiations between the two competent authorities. Conditioning the settlement on MAP would delay resolution and could jeopardize the Appeals settlement. However, PPC should take care to preserve its MAP rights by filing a MAP request with the U.S. Competent Authority within the applicable timeframe (generally within three years of the first notification of the action giving rise to double taxation).
Additionally, any settlement documentation, including Form 906 (Closing Agreement), should be drafted to preserve PPC's ability to pursue MAP relief. C&H will ensure that the settlement terms do not inadvertently waive or limit PPC's Treaty rights.
VIII. Alternative — Tax Court Litigation
A. Costs and Timeline
In the event that Appeals negotiations fail to produce an acceptable settlement, or if the Appeals Officer's best offer exceeds the 20% hard ceiling, PPC would receive a statutory notice of deficiency (commonly referred to as the "90-Day Letter") and would have 90 days to file a petition with the United States Tax Court.
C&H estimates the following costs and timeline associated with Tax Court litigation:
• Timeline to Trial: Approximately 2 to 4 years from the date of petition filing. Transfer pricing cases are among the most complex matters on the Tax Court's docket and typically involve extensive pre-trial discovery, expert depositions, and pre-trial motion practice. Trial itself may last several weeks.
• Estimated Litigation Costs: C&H estimates total additional legal fees of approximately $6 million to $10 million for Tax Court proceedings, including preparation of the petition, discovery, pre-trial briefing, trial preparation, and trial. Whitmore Valuation Group's expert witness testimony fees would add approximately $2 million to $5 million, including preparation of expert reports, depositions, and trial testimony. Total estimated incremental professional fees for Tax Court litigation: approximately $8 million to $15 million beyond current engagement costs.
• Adverse Precedent Risk: Tax Court proceedings are public, and a published opinion could establish adverse precedent affecting PPC's transfer pricing arrangements for future tax years. Even a partially favorable outcome could include language that the IRS might use in future examinations.
• Reputational Considerations: Tax Court proceedings are a matter of public record. The details of PPC's intercompany transactions, Irish operations, and transfer pricing methodology would become publicly available, potentially attracting attention from the media, competitors, and the investment community.
B. Probability Assessment
C&H believes that a settlement within the recommended range of 10–15% of the proposed adjustment is achievable at the Appeals level. The hazards of litigation analysis demonstrates that the IRS's positions contain significant vulnerabilities, and Appeals Officers in transfer pricing cases routinely settle at substantial discounts to proposed adjustments. The overall profile of this case — strong taxpayer documentation, credible independent economic analysis, robust economic substance, and identifiable weaknesses in the IRS's comparable analysis — is conducive to a favorable settlement at Appeals.
A settlement at Appeals avoids the uncertainty, cost, and reputational risk associated with public Tax Court proceedings. It also avoids the potential adverse impact on PPC's common stock (traded on Nasdaq under the symbol "PPCA"), credit relationships, and regulatory standing. The financial and strategic benefits of administrative resolution significantly outweigh the marginal improvement in outcome that might be achieved through litigation.
C&H remains prepared to litigate in the Tax Court if necessary, and PPC's willingness to do so is an important element of its negotiating leverage at Appeals. However, litigation should be viewed as a fallback option, to be pursued only if the Appeals process does not produce a result within the authorized parameters.
IX. Recommended Authorization
A. Specific Recommendations
Based on the foregoing analysis, C&H respectfully requests that PPC management authorize the following settlement parameters:
1. Target Resolution Range. C&H is authorized to negotiate at IRS Appeals with a target resolution range of 10–15% of the $380.4 million net proposed adjustment, corresponding to a total income adjustment of $38.04 million to $57.06 million across tax years 2017–2020, with a preferred midpoint of approximately $47.6 million (12.5%).
2. Hard Ceiling. The maximum authorized settlement is 20% of the proposed adjustment ($76.08 million total income adjustment). Any settlement above this amount requires additional approval from CEO Catherine Falk and CFO Rajesh Iyer before execution.
3. Penalty Abatement. Full abatement of the IRC § 6662(e) substantial valuation misstatement penalty (approximately $15.98 million) is a non-negotiable condition of any settlement. C&H is not authorized to agree to any settlement that includes acceptance of any portion of the penalty.
4. Year-by-Year Allocation. Any agreed adjustment shall be allocated across tax years 2017–2020 on a principled basis consistent with the relative magnitude of the IRS's proposed adjustments for each year. C&H is authorized to negotiate the specific allocation within the overall approved settlement amount without requiring additional authorization, provided the total adjustment remains within the approved parameters.
5. Settlement Documentation. C&H is authorized to execute settlement documents on behalf of PPC, including IRS Form 906 (Closing Agreement on Final Determination Covering Specific Matters), within the approved parameters. C&H will provide copies of all executed settlement documents to PPC management and General Counsel promptly upon execution.
B. Requested Approvals
C&H requests that the following approvals be confirmed in writing:
• Marcus Whitfield, Vice President, Global Tax: Confirmation of settlement authority within the parameters described in Section IX.A above.